Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
about
Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptorThe TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancerHormone response in ovarian cancer: time to reconsider as a clinical target?Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.Chemical castration and anti-androgens induce differential gene expression in prostate cancer.Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone AnalogsCarbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.99mTc-LHRH in tumor receptor imaging.Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer.Short-term buserelin administration induces apoptosis and morphological changes in adult rat testes.Androgen pathway manipulation and survival in patients with lung cancer.Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
P2860
Q21284425-469D8B63-9AA5-46B8-9622-848F4E921FF6Q35582540-E3E5B9C7-0E21-4DC9-92D4-F3DE942DD1AFQ36966197-8EA8C803-551E-414E-836B-E1BB9F71F9C8Q37859389-DB20AEF2-5729-49C0-A12E-48ED1E561FAFQ38132229-27B974A1-6983-462A-9C83-53EE0BEB2597Q38324695-1ABE2A86-C6BD-4509-A3FB-3F1DAC830DDDQ38326753-F6DAA051-F463-4EE9-A0F5-1BF53E29F5B8Q38877441-B887BF79-BEB8-4BBA-A9CA-4BF0A362E4A8Q39445456-AC1E073B-881A-4A0D-87CF-4B349DFAD20BQ39586391-D244F887-F88E-4E6A-9954-238FEDD92651Q40979226-A4F63E8E-DAFD-4C14-9E2B-94BB406CF242Q49912857-C29BC248-022E-44AA-8EDA-64D7FBBC942BQ51097168-A1B0A7DA-06F4-46C1-97BD-F6EAB0C6A655Q53576123-A7F8B806-63E0-44D0-89EE-6DD48839D8A4Q53773544-4BE90F63-3544-47E1-8875-968AF9C25A21Q57106289-3B77D035-9E73-461D-85EE-2047E991267A
P2860
Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@ast
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@en
type
label
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@ast
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@en
prefLabel
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@ast
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@en
P2093
P1476
Luteinizing hormone-releasing ...... lopment, and place in therapy.
@en
P2093
Jacques-Pierre Moreau
Joëlle Blumberg
Patrick Delavault
P304
P356
10.1016/J.CLINTHERA.2006.10.018
P577
2006-10-01T00:00:00Z